CASI logo

CASI Pharmaceuticals (CASI) Company Overview

Profile

Full Name:

CASI Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

China

IPO:

June 12, 1996

Indexes:

Not included

Description:

CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer and other diseases. They aim to improve patient outcomes through advanced research and partnerships, offering new treatment options in the global healthcare market.

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jun 2, 2022

Analyst ratings

Recent major analysts updates

May 15, 24 HC Wainwright & Co.
Buy
Nov 15, 23 HC Wainwright & Co.
Buy
Aug 14, 23 HC Wainwright & Co.
Buy
May 22, 23 HC Wainwright & Co.
Buy
Nov 16, 22 BTIG
Buy
Nov 15, 22 HC Wainwright & Co.
Buy
Aug 15, 22 HC Wainwright & Co.
Buy
Jun 3, 22 BTIG
Buy
May 16, 22 HC Wainwright & Co.
Buy
May 18, 21 BTIG
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for CASI Pharmaceuticals?
  • Does CASI Pharmaceuticals pay dividends?
  • What sector is CASI Pharmaceuticals in?
  • What industry is CASI Pharmaceuticals in?
  • What country is CASI Pharmaceuticals based in?
  • When did CASI Pharmaceuticals go public?
  • Is CASI Pharmaceuticals in the S&P 500?
  • Is CASI Pharmaceuticals in the NASDAQ 100?
  • Is CASI Pharmaceuticals in the Dow Jones?
  • When was CASI Pharmaceuticals's last earnings report?
  • When does CASI Pharmaceuticals report earnings?
  • Should I buy CASI Pharmaceuticals stock now?

What is the ticker symbol for CASI Pharmaceuticals?

The ticker symbol for CASI Pharmaceuticals is NASDAQ:CASI

Does CASI Pharmaceuticals pay dividends?

No, CASI Pharmaceuticals does not pay dividends

What sector is CASI Pharmaceuticals in?

CASI Pharmaceuticals is in the Healthcare sector

What industry is CASI Pharmaceuticals in?

CASI Pharmaceuticals is in the Biotechnology industry

What country is CASI Pharmaceuticals based in?

CASI Pharmaceuticals is headquartered in China

When did CASI Pharmaceuticals go public?

CASI Pharmaceuticals's initial public offering (IPO) was on June 12, 1996

Is CASI Pharmaceuticals in the S&P 500?

No, CASI Pharmaceuticals is not included in the S&P 500 index

Is CASI Pharmaceuticals in the NASDAQ 100?

No, CASI Pharmaceuticals is not included in the NASDAQ 100 index

Is CASI Pharmaceuticals in the Dow Jones?

No, CASI Pharmaceuticals is not included in the Dow Jones index

When was CASI Pharmaceuticals's last earnings report?

CASI Pharmaceuticals's most recent earnings report was on Nov 14, 2024

When does CASI Pharmaceuticals report earnings?

The next expected earnings date for CASI Pharmaceuticals is Mar 28, 2025

Should I buy CASI Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions